To include your compound in the COVID-19 Resource Center, submit it here.

Approval watch

Approval watch

Selected products up for approval in 2009. (A) Endo (NASDAQ:ENDP) is acquiringIndevus (NASDAQ:IDEV); (B) FDA missed Sept. 26, 2008 PDUFA date; (C) For Myozyme alglucosidase produced at the 2,000 liter bioreactor scale; (D) In September 2008, NovoNordisk (CSE:NVO; NYSE:NVO) said FDA would likely need to extend the March 23, 2009 PDUFA date by a couple of months

Company Product Indication Event Milestone
Abbott (NYSE:ABT)/Takeda (Tokyo:4502) TAK-390MR Gastroesophageal reflux disease (GERD) PDUFA date

Read the full 821 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers